Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation
Smith Giri1,2, Dee Lin3, Ruth Wangia Dixon4
1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Background:
B-cell maturation antigen (BCMA)-targeted therapies were approved for triple-class exposed relapsed/refractory multiple myeloma (RRMM) after ≥4 lines of therapy.
Methods:
This claims-based retrospective analysis examined clinical and economic burden among United States patients who met eligibility for BCMA-targeted therapies and started a new therapy between 1 January 2016 and 30 September 2022.
Results:
Of 228 eligible patients (median age: 64, 52.6% male, 68.7% White), clinical burden was characterized by prevalent MM-related conditions and complications, and high treatment failure rate (44.7% in 6 months). Hospitalization rate increased from 48.3% to 71.1%, while healthcare costs per-member-per-month increased from $35,964 during 12-month baseline to $41,358 during follow-up (median: 11.8 months).
Conclusions:
Patients with heavily pre-treated RRMM endure high disease burden and could benefit from novel therapies.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...